Skip to main content
. Author manuscript; available in PMC: 2018 Jan 15.
Published in final edited form as: Circulation. 2017 Jun 21;136(18):1688–1702. doi: 10.1161/CIRCULATIONAHA.117.028261

Figure 5. Cost-effectiveness.

Figure 5

A, Cost-effectiveness plane showing incremental costs and quality-adjusted life-years (QALYs) of closed tunnel (CT) endoscopic vein harvesting (EVH) and open tunnel (OT)-EVH vs open vein harvesting (OVH). Bootstrap replicates (n=2000) show the uncertainty with the larger points showing the point estimates. A cost-effectiveness threshold of £20 000 per QALY is presented. For a technology in the northeast quadrant, a cost-effective technology is one where the point estimate and a high proportion of bootstrap replicate falls below (southeast) the threshold line. B, Cost-effectiveness acceptability curve for OVH, CT-EVH, and OT-EVH plotted by calculating the proportion of bootstrap replicates falling below the cost-effectiveness threshold line as the threshold is varied. The typical threshold used by the National Institute for Health and Care Excellence is taken to be between £20 000 and £30 000 per QALY.